Rhegen Bio

Rhegen Bio is a private Chinese biotechnology company focused on mRNA medicines and vaccines. The company has built an end-to-end mRNA platform spanning protein design, mRNA sequence engineering, synthesis, formulation, lyophilization, and delivery systems, including carrier-free and lipid nanoparticle approaches. Its pipeline is concentrated in infectious disease vaccines and emerging oncology applications, with clinical activity reported for products such as RH110 for herpes zoster, RH109 for COVID-19 booster vaccination, RH119 for tuberculosis, and RG015A for personalized cancer vaccination. Rhegen also operates an external mRNA solutions business through its subsidiary InnoBio and positions its technology around differentiated stability, storage, and druggability advantages. Overall, the company appears to be a platform-oriented mRNA biotech advancing both internal pipeline assets and partnering/service capabilities.